BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11981148)

  • 1. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study.
    Levy JH; Despotis GJ; Szlam F; Olson P; Meeker D; Weisinger A
    Anesthesiology; 2002 May; 96(5):1095-102. PubMed ID: 11981148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation.
    Slaughter TF; Mark JB; El-Moalem H; Hayward KA; Hilton AK; Hodgins LP; Greenberg CS
    Blood Coagul Fibrinolysis; 2001 Jan; 12(1):25-31. PubMed ID: 11229823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of heparin resistance with Antithrombin III in cardiac surgery.
    Kanbak M
    Can J Anaesth; 1999 Jun; 46(6):581-5. PubMed ID: 10391608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation.
    Despotis GJ; Levine V; Joist JH; Joiner-Maier D; Spitznagel E
    Anesth Analg; 1997 Sep; 85(3):498-506. PubMed ID: 9296400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery.
    Jooste EH; Scholl R; Wu YH; Jaquiss RDB; Lodge AJ; Ames WA; Homi HM; Machovec KA; Greene NH; Donahue BS; Shah N; Benkwitz C
    J Cardiothorac Vasc Anesth; 2019 Feb; 33(2):396-402. PubMed ID: 30072263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study.
    Dietrich W; Dilthey G; Spannagl M; Jochum M; Braun SL; Richter JA
    Anesthesiology; 1995 Oct; 83(4):679-89; discussion 29A-30A. PubMed ID: 7574046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial antithrombin-III deficiency during cardiopulmonary bypass: a case report.
    Brinks HJ; Weerwind PW; Verkroost MW; Nováková I; Brouwer MH
    Perfusion; 2000 Nov; 15(6):553-6. PubMed ID: 11131221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery.
    Lemmer JH; Despotis GJ
    J Thorac Cardiovasc Surg; 2002 Feb; 123(2):213-7. PubMed ID: 11828278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical treatment of atrial septal defect in a patient with familial antithrombin-III deficiency.
    Hattori T; Hata M; Sezai A; Wakui S; Shiono M
    Ann Thorac Cardiovasc Surg; 2013; 19(4):323-5. PubMed ID: 23232305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass.
    Paparella D; Al Radi OO; Meng QH; Venner T; Teoh K; Young E
    Blood Coagul Fibrinolysis; 2005 Jul; 16(5):323-8. PubMed ID: 15970715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
    Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
    Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pilot Study of Antithrombin Replacement Prior to Cardiopulmonary Bypass in Neonates.
    Niebler RA; Woods KJ; Murkowski K; Ghanayem NS; Hoffman G; Mitchell ME; Punzalan RC; Scott JP; Simpson P; Tweddell JS
    Artif Organs; 2016 Jan; 40(1):80-5. PubMed ID: 26620919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Heparin-Resistant Patients with Benefits? Maximizing Biocompatibility in Cardiopulmonary Bypass: Combining ATryn® Recombinant Antithrombin III and Carmeda® Heparin-Bonded Perfusion Circuits: A Case Series.
    Chryssos A; Stroup SJ; Pifer MM; Tawil M; Conrad CG
    J Extra Corpor Technol; 2015 Mar; 47(1):44-7. PubMed ID: 26390679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers.
    Slaughter TF; LeBleu TH; Douglas JM; Leslie JB; Parker JK; Greenberg CS
    Anesthesiology; 1994 Mar; 80(3):520-6. PubMed ID: 8141448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
    Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Joiner-Maier D; Santoro SA; Spitznagel E; Weitz JI; Goodnough LT
    Thromb Haemost; 1996 Dec; 76(6):902-8. PubMed ID: 8972009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of antithrombin iii concentrations during cardiopulmonary surgery].
    Sonzogni V; Bellavita P; Carrara B; Cossolini M; Ferri F; Fabretti F; Mamprin F; Pelliccioli I
    Minerva Anestesiol; 2000; 66(1-2):17-23. PubMed ID: 10736978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.